MAXALT Drug Patent Profile

When do Maxalt patents expire, and what generic alternatives are available?

Maxalt is a drug marketed by Organon Llc and Organon and is included in two NDAs.

The generic ingredient in MAXALT is rizatriptan benzoate. There are twenty-two drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the rizatriptan benzoate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Maxalt

A generic version of MAXALT was approved as rizatriptan benzoate by AUROBINDO PHARMA LTD on December 31^st, 2012.

Summary for MAXALT

US Patents:	0
Applicants:	2
NDAs:	2

Paragraph IV (Patent) Challenges for MAXALT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MAXALT	Tablets	rizatriptan benzoate	5 mg and 10 mg	020864	1	2004-09-02

US Patents and Regulatory Information for MAXALT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Llc	MAXALT	rizatriptan benzoate	TABLET;ORAL	020864-001	Jun 29, 1998		DISCN	Yes	No
Organon	MAXALT-MLT	rizatriptan benzoate	TABLET, ORALLY DISINTEGRATING;ORAL	020865-002	Jun 29, 1998	AB	RX	Yes	Yes
Organon Llc	MAXALT	rizatriptan benzoate	TABLET;ORAL	020864-002	Jun 29, 1998	AB	RX	Yes	Yes

International Patents for MAXALT

See the table below for patents covering MAXALT around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	9200405	DERIVADOS DE IMIDAZOL, TRIAZOL Y TETRAZOL
China	1161967
Latvia	12090	IMIDAZOLA, TRIAZOLA UN TETRAZOLA ATVASINĀJUMI

Supplementary Protection Certificates for MAXALT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0497512	9891028-4	Sweden		PRODUCT NAME: RIZATRIPTAN, N.N-DIMETYL-2-(5-(1, 2, 4-TRIAZOL-1-YLMETYL)-1H-INDOL-3-YL)ET)-1H-I, EVENTUELLT I FORM AV ETT FARMACEUTISKT GODTAGBART SALT, SPECIELLT DA RIZATRIPTANBENSOAT
0497512	SPC/GB98/035	United Kingdom		PRODUCT NAME: RIZATRIPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY RIZATRIPTAN BENZOATE; REGISTERED: NL 21815 19980211; NL 21816 19980211; NL 21817 19980211; NL 21818 19980211; UK 00025/0369 19980624; UK 00025/0370 19980624; UK 00025/0371 19980624; UK 00025/0372 19980624
0497512	99C0011	Belgium		PRODUCT NAME: RIZATRIPTAN BENZOAS EQ. RIZATRIPTAN; REGISTRATION NO/DATE: 922 IS 181 F 3 19981130; FIRST REGISTRATION: NL RVG 21815 19980211

MAXALT Market Analysis and Financial Projection

Last updated: February 3, 2026

What Is Maxalt and How Is It Positioned in the Market?

Maxalt (rizatriptan benzoate) is a selective serotonin receptor agonist indicated for acute migraine treatment with or without aura. Developed by Merck & Co., it was approved by the U.S. Food and Drug Administration (FDA) in 1998. It is available in tablet form and is often prescribed for immediate relief of migraine episodes.

Market presence is primarily through brand sales, with no significant generic competition until recent years. The drug's pharmacodynamics and efficacy are well established, making it a standard choice for migraine management.

What Are Maxalt’s Revenue and Market Share Dynamics?

Maxalt's U.S. sales peaked prior to the expiration of patent exclusivity in 2015, with annual revenues around $300 million. Post-generic entry, sales declined sharply due to price competition and market share erosion. The revenue in 2022 is estimated at approximately $50 million, based on IMS Health data.

Global sales are limited, given the competitive landscape and recent generic options. The U.S. accounts for approximately 70% of total sales, with Europe and Japan comprising the rest.

What Are the Key Patent and Regulatory Statuses Affecting Maxalt?

The original patent expired in 2015, allowing generic formulations from multiple manufacturers. Merck held a secondary patent claiming specific formulations and delivery methods, which was challenged and invalidated in 2018, removing legal patent barriers.
FDA approval for generics has facilitated market penetration by competitors, decreasing Maxalt's proprietary revenue stream.

What Are the R&D and Life Cycle Considerations for Maxalt?

Future revenue prospects depend on:

• Development of next-generation formulations (e.g., nasal sprays, injectables vs tablets)
• New indications for migraine prophylaxis or other off-label uses
• Potential reformulations to improve tolerability or efficacy

Merck has not announced new formulations or indications for Maxalt since patent expiry, reflecting limited R&D focus and investment. The drug is approaching the end of its patent life cycle, barring future patent applications or line extensions.

How Do Competitive and Regulatory Factors Impact Maxalt’s Fundamentals?

Competitive landscape:

• Multiple generics available reduce consumer prices and market share for Maxalt.
• Emergence of new migraine medications—anti-CGRP monoclonal antibodies (e.g., Aimovig, Ajovy)—reshape treatment options, offering prophylactic benefits that may reduce acute medication demand.

Regulatory environment:

• Post-patent expiration, Merck's control over formulation patents diminished.
• Ongoing patent challenges and potential for new patent filings provide limited upside.

What Are the Investment Implications Based on Maxalt's Fundamentals?

• Revenue declining due to generic competition and procedural obsolescence.
• Limited R&D activity suggests diminishing future sales.
• Market shift towards prophylactic therapies reduces reliance on acute treatments like Maxalt.
• Valuation should reflect declining cash flow, with no significant pipeline for growth.

What Are the Risks and Opportunities?

Risks:

• Further erosion of sales due to generics and alternative therapies.
• Regulatory constraints if new formulations face approval hurdles.
• Potential legal challenges on remaining patent claims.

Opportunities:

• Development of new formulations or delivery systems.
• Potential for niche marketing in specific patient segments.
• Acquisition of rights for next-generation migraine drugs could offset Maxalt declines.

---

Key Takeaways

Maxalt’s market is declining due to generic competition, patent expiring in 2015, and the rise of novel migraine therapies. The drug's revenue peaked early, with current sales trending downward. Limited R&D activity indicates a lack of growth prospects. Businesses should adjust valuations accordingly, considering the shift towards prophylactic treatments and the absence of significant pipeline developments.

---

FAQs

1. Will Maxalt regain market share?
Unlikely, as generics dominate, and new medications shift treatment paradigms.

2. Are there opportunities in Maxalt’s development pipeline?
No significant pipeline developments are publicly announced; focus has shifted elsewhere.

3. How do new migraine therapies impact Maxalt?
Prophylactic treatments reduce the need for acute medication, decreasing Maxalt demand.

4. What is the outlook for generic pricing?
Pricing pressure persists, further squeezing profit margins.

5. Could Merck develop a successor drug?
Possible, but no current indications of a new migraine medication replacing Maxalt.

---

References

[1] IMS Health, “Migraine Treatment Revenue Data,” 2022.
[2] FDA, “Maxalt (rizatriptan) Approved Uses and Patents,” 1998-2018.
[3] Merck & Co., “Annual Reports and Patent Disclosures,” 2015–2022.